meta|Evidence - COVID-19
click on circles to display study description...
famotidine (n=10) vs. placebo (n=10)
randomized controlled trial some concerns about risk of bias
Famotidine.
Oral famotidine 160 mg four times a day until the day of discharge, for a maximum of fourteen days plus standard of care.
Placebo
Placebo in form of oral tablets four times a day until the day of discharge or for a maximum of fourteen days plus standard of care.
All patients received standard of care. Standard pharmacotherapy according to the National Committee of COVID-19 treatment protocols included: (i) Hydroxychloroquine/chloroquine phosphate: Hydroxychloroquine sulfate tablets 200 mg or chloroquine phosphate tablets 250 mg (equivalent to 150 mg base amount); 2 tablets every 12 hours on the first day and then 1 tablet every 12 hours for at least 7 days and up to 14 days. (ii) One of the following medications at the discretion of the treating physician: Kaletra tablets (lopinavir/ritonavir) 200/50 mg; 2 tablets every 12 hours after meals for at least 7 days and up to 14 days. (iii) Atazanavir/Ritonavir 300/100 tablet: 1 tablet a day with food; or Atazanavir 400 mg daily for a minimum of 7 days and a maximum of 14 days.
COVID 19 hospitalized
All COVID-19 patients admitted to Shahid Mohammadi Hospital in Bandar Abbas whose PCR test results are positive for SARS-Cov-2 and sign the written consent of the study
Single-blind.
Single center, Shahid Mohammadi Hospital in Bandar Abbas, Iran.
The lead researcher, care givers, data collectors, and outcome assessors are aware of the grouping of patients.
powered by vis.js Network